[{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"||Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"||Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"||Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"||Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for elvanse

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.

                          Product Name : Vyvanse-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 30, 2025

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Granules India

                          02

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.

                          Product Name : Vyvanse-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Granules India

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.

                          Product Name : Vyvanse-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 31, 2023

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.

                          Product Name : Vyvanse-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 09, 2023

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aaron Keshen

                          Country arrow
                          EPSC
                          Not Confirmed

                          Aaron Keshen

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 12, 2018

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Nova Scotia Health Authority

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          JPM van Stralen Medicine Professional

                          Country arrow
                          EPSC
                          Not Confirmed

                          JPM van Stralen Medicine Professional

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 09, 2017

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          King's College London

                          Country arrow
                          EPSC
                          Not Confirmed

                          King's College London

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 07, 2017

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Guanfacine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Vyvanse

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 24, 2017

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          North Dakota State University

                          Country arrow
                          EPSC
                          Not Confirmed

                          North Dakota State University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 03, 2017

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : SHIRE PLC | Neuropsychiatric Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Vanderbilt University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Vanderbilt University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 18, 2016

                          Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase IV

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank